Your browser doesn't support javascript.
loading
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.
Garrido-Cano, Iris; Adam-Artigues, Anna; Lameirinhas, Ana; Blandez, Juan F; Candela-Noguera, Vicente; Lluch, Ana; Bermejo, Begoña; Sancenón, Felix; Cejalvo, Juan Miguel; Martínez-Máñez, Ramón; Eroles, Pilar.
Afiliação
  • Garrido-Cano I; Biomedical Research Institute INCLIVA, Valencia 46010, Spain.
  • Adam-Artigues A; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia 46010, Spain.
  • Lameirinhas A; Biomedical Research Institute INCLIVA, Valencia 46010, Spain.
  • Blandez JF; Biomedical Research Institute INCLIVA, Valencia 46010, Spain.
  • Candela-Noguera V; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia 46010, Spain.
  • Lluch A; CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid 28029, Spain.
  • Bermejo B; Unidad Mixta de Investigación en Nanomedicina y Sensores, Universitat Politècnica de València, IIS La Fe, Valencia 46026, Spain.
  • Sancenón F; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia 46010, Spain.
  • Cejalvo JM; Biomedical Research Institute INCLIVA, Valencia 46010, Spain.
  • Martínez-Máñez R; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain.
  • Eroles P; Universitat de València, Valencia 46010, Spain.
ACS Appl Mater Interfaces ; 15(32): 38323-38334, 2023 Aug 16.
Article em En | MEDLINE | ID: mdl-37549382
ABSTRACT
Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this context, microRNAs have emerged as potential therapeutic targets but still present some limitations for in vivo applications. Particularly, miR-200c-3p is a well-known tumor suppressor microRNA that inhibits tumor progression and metastasis in breast cancer through downregulating ZEB1 and ZEB2. Based on the above, we describe the design and validation of a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery for breast cancer treatment. We demonstrate the biocompatibility of the synthesized nanodevices as well as their ability to escape from endosomes/lysosomes and inhibit tumorigenesis, invasion, migration, and proliferation of tumor cells in vitro. Moreover, tumor targeting and effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mouse model, and the therapeutic efficacy is also evidenced by a decrease in tumor size and lung metastasis, while showing no signs of toxicity. Overall, our results provide evidence that miR-200c-3p-loaded nanoparticles are a potential strategy for breast cancer therapy and a safe and effective system for tumor-targeted delivery of microRNAs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Nanopartículas / Neoplasias Pulmonares Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Nanopartículas / Neoplasias Pulmonares Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article